Protocol Ledger

NCT05161481 · Phase II · TERMINATED

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Interventional Phase II clinical trial protocol NCT05161481 sponsored by Boehringer Ingelheim in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-04-27 Enrollment: 80 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05161481
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05161481
Protocol FieldVerified Registry Value
NCT IdentifierNCT05161481
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment80 participants (ACTUAL)
Registered Start Date2022-04-27
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05161481
Hospital Research SiteLocationSite Profile
Medical University of South CarolinaCharleston, SCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI